Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody.
The increasing incidence of acyclovir (ACV) and multidrug-resistant strains in patients with corneal HSV-1 infections leading to Herpetic Stromal Keratitis (HSK) is a major health problem in industrialized countries and often results in blindness. To overcome this obstacle, we have previously develo...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4294644?pdf=render |
| _version_ | 1819231701811855360 |
|---|---|
| author | Adalbert Krawczyk Miriam Dirks Maren Kasper Anna Buch Ulf Dittmer Bernd Giebel Lena Wildschütz Martin Busch Andre Goergens Karl E Schneweis Anna M Eis-Hübinger Beate Sodeik Arnd Heiligenhaus Michael Roggendorf Dirk Bauer |
| author_facet | Adalbert Krawczyk Miriam Dirks Maren Kasper Anna Buch Ulf Dittmer Bernd Giebel Lena Wildschütz Martin Busch Andre Goergens Karl E Schneweis Anna M Eis-Hübinger Beate Sodeik Arnd Heiligenhaus Michael Roggendorf Dirk Bauer |
| author_sort | Adalbert Krawczyk |
| collection | DOAJ |
| description | The increasing incidence of acyclovir (ACV) and multidrug-resistant strains in patients with corneal HSV-1 infections leading to Herpetic Stromal Keratitis (HSK) is a major health problem in industrialized countries and often results in blindness. To overcome this obstacle, we have previously developed an HSV-gB-specific monoclonal antibody (mAb 2c) that proved to be highly protective in immunodeficient NOD/SCID-mice towards genital infections. In the present study, we examined the effectivity of mAb 2c in preventing the immunopathological disease HSK in the HSK BALB/c mouse model. Therefore, mice were inoculated with HSV-1 strain KOS on the scarified cornea to induce HSK and subsequently either systemically or topically treated with mAb 2c. Systemic treatment was performed by intravenous administration of mAb 2c 24 h prior to infection (pre-exposure prophylaxis) or 24, 40, and 56 hours after infection (post-exposure immunotherapy). Topical treatment was performed by periodical inoculations (5 times per day) of antibody-containing eye drops as control, starting at 24 h post infection. Systemic antibody treatment markedly reduced viral loads at the site of infection and completely protected mice from developing HSK. The administration of the antiviral antibody prior or post infection was equally effective. Topical treatment had no improving effect on the severity of HSK. In conclusion, our data demonstrate that mAb 2c proved to be an excellent drug for the treatment of corneal HSV-infections and for prevention of HSK and blindness. Moreover, the humanized counterpart (mAb hu2c) was equally effective in protecting mice from HSV-induced HSK when compared to the parental mouse antibody. These results warrant the future development of this antibody as a novel approach for the treatment of corneal HSV-infections in humans. |
| first_indexed | 2024-12-23T11:49:09Z |
| format | Article |
| id | doaj.art-32953f39b1bb43efa050a355fa8280ba |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-23T11:49:09Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-32953f39b1bb43efa050a355fa8280ba2022-12-21T17:48:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01101e011680010.1371/journal.pone.0116800Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody.Adalbert KrawczykMiriam DirksMaren KasperAnna BuchUlf DittmerBernd GiebelLena WildschützMartin BuschAndre GoergensKarl E SchneweisAnna M Eis-HübingerBeate SodeikArnd HeiligenhausMichael RoggendorfDirk BauerThe increasing incidence of acyclovir (ACV) and multidrug-resistant strains in patients with corneal HSV-1 infections leading to Herpetic Stromal Keratitis (HSK) is a major health problem in industrialized countries and often results in blindness. To overcome this obstacle, we have previously developed an HSV-gB-specific monoclonal antibody (mAb 2c) that proved to be highly protective in immunodeficient NOD/SCID-mice towards genital infections. In the present study, we examined the effectivity of mAb 2c in preventing the immunopathological disease HSK in the HSK BALB/c mouse model. Therefore, mice were inoculated with HSV-1 strain KOS on the scarified cornea to induce HSK and subsequently either systemically or topically treated with mAb 2c. Systemic treatment was performed by intravenous administration of mAb 2c 24 h prior to infection (pre-exposure prophylaxis) or 24, 40, and 56 hours after infection (post-exposure immunotherapy). Topical treatment was performed by periodical inoculations (5 times per day) of antibody-containing eye drops as control, starting at 24 h post infection. Systemic antibody treatment markedly reduced viral loads at the site of infection and completely protected mice from developing HSK. The administration of the antiviral antibody prior or post infection was equally effective. Topical treatment had no improving effect on the severity of HSK. In conclusion, our data demonstrate that mAb 2c proved to be an excellent drug for the treatment of corneal HSV-infections and for prevention of HSK and blindness. Moreover, the humanized counterpart (mAb hu2c) was equally effective in protecting mice from HSV-induced HSK when compared to the parental mouse antibody. These results warrant the future development of this antibody as a novel approach for the treatment of corneal HSV-infections in humans.http://europepmc.org/articles/PMC4294644?pdf=render |
| spellingShingle | Adalbert Krawczyk Miriam Dirks Maren Kasper Anna Buch Ulf Dittmer Bernd Giebel Lena Wildschütz Martin Busch Andre Goergens Karl E Schneweis Anna M Eis-Hübinger Beate Sodeik Arnd Heiligenhaus Michael Roggendorf Dirk Bauer Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody. PLoS ONE |
| title | Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody. |
| title_full | Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody. |
| title_fullStr | Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody. |
| title_full_unstemmed | Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody. |
| title_short | Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody. |
| title_sort | prevention of herpes simplex virus induced stromal keratitis by a glycoprotein b specific monoclonal antibody |
| url | http://europepmc.org/articles/PMC4294644?pdf=render |
| work_keys_str_mv | AT adalbertkrawczyk preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT miriamdirks preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT marenkasper preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT annabuch preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT ulfdittmer preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT berndgiebel preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT lenawildschutz preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT martinbusch preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT andregoergens preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT karleschneweis preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT annameishubinger preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT beatesodeik preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT arndheiligenhaus preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT michaelroggendorf preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody AT dirkbauer preventionofherpessimplexvirusinducedstromalkeratitisbyaglycoproteinbspecificmonoclonalantibody |